Skip to content

Half effective dose of oliceridine combined with propofol for bidirectional endoscopy in subclinically obese patients

Half effective dose of oliceridine combined with propofol for bidirectional endoscopy in subclinically obese patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400095070
Enrollment
Unknown
Registered
2024-12-31
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical obesity

Interventions

2.0mg group:Subclinically obese patients undergoing bidirectional endoscopy under unintubated sedation anesthesia were placed on a sedation regimen of oliceridine (test dose) combined with propofol (2
If the intraoperative reaction in the previous subject was a negative response, the dose of oliceridine administered to the next subject was decreased by one dose gradient until the subject had a posi
2.5mg group:Subclinically obese patients undergoing bidirectional endoscopy under unintubated sedation anesthesia were placed on a sedation regimen of oliceridine (test dose) combined with propofol (2

Sponsors

The Fifth People's Hospital of Huai'an
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1,Subjects clearly understand, voluntarily participate in the study, and sign an informed consent form by themselves;2, ASA class I-II;3,Aged 18 to 65 years; 4,BMI>=28 kg/?; 5,Elective bidirectional endoscopy.

Exclusion criteria

Exclusion criteria: 1,Presence of speech communication, vision, or hearing impairments;2, Presence of psychosomatic or neurological disorders;3, Presence of acute or severe bronchial asthma, Mallampati classification >3, severe difficult airways, and severe sleep apnea using a ventilator;4, Known or suspected gastrointestinal obstruction;5,Participation as a subject in a clinical trial of another drug within the past 3 months;6,Allergy to or contraindication to propofol, opioids, and their drug components;7,Treatment with sedative and hypnotic medications within the past 48 hours,as well as alcohol or drug abuse;8,Examination time more than 30 minutes;9,Participation in this trial is deemed inappropriate by the investigator.

Design outcomes

Primary

MeasureTime frame
Gastroscope placement reaction;

Secondary

MeasureTime frame
Oliceridine dose;Mean arterial pressure at each time point;Time of examination;Bracketed jaw condition;Vasoactive drug use;Total propofol dose;Heart rate at each time point;Oxygen saturation at each time point;Time of awakening;Time of leaving the hospital;Mask pressurization;Use of antagonistic drugs;Perioperative hypotension;Perioperative bradycardia;Decreased perioperative oxygen saturation;Other perioperative adverse reactions;

Countries

China

Contacts

Public ContactYongjiu Ji

The Fifth People's Hospital of Huai'an

330729093@qq.com+86 159 9619 5590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026